Stimuli‐responsive crosslinked nanomedicine for cancer treatment

Abstract

Nanomedicines are attractive paradigms to deliver drugs, contrast agents, immunomodulators, and gene editors for cancer therapy and diagnosis. However, the currently developed nanomedicine suffers from poor serum stability, premature drug release, and lack of responsiveness. Crosslinking strategy can be utilized to overcome these shortcomings by employing stimuli‐responsive chemical bonds to tightly hold the nanostructure and releasing the payloads spatiotemporally in a highly controlled manner. In this Review, we summarize the recently ingenious design of the stimuli‐responsive crosslinked nanomedicines (SCN) in the field of cancer treatment and their advances in circumventing the drawbacks of the conventional drug delivery system. We classify the SCNs into three categories based on the crosslinking strategies, including built‐in, on‐surface, and inter‐particle crosslinking nanomedicines. Thanks to the stimuli‐responsive crosslinkages, SCNs are capable of keeping robust stability during systemic circulation. They also respond to the particular tumoral conditions to experience a series of dynamic changes, such as the changes in size, surface charge, targeting moieties, integrity, and imaging signals. These characteristics allow them to efficiently overcome different biological barriers and substantially improve the drug delivery efficiency, tumor‐targeting ability, and imaging sensitivities. With the examples discussed, we envision that our perspectives can inspire more attempts to engineer intelligent nanomedicine to achieve effective cancer therapy and diagnosis.

Highly Retina-Permeating and Long-Acting Resveratrol/Metformin Nanotherapeutics for Enhanced Treatment of Macular Degeneration

“…Nanocarriers such as liposomes and mesoporous silica nanoparticles (NPs) and other functional NPs have been demonstrated as effective nanosystems for synchronic delivery of multiple drugs and disease treatments. − Because of their intrinsic structures, liposomes are able to encapsulate both hydrophilic and hydrophobic drugs in their core and shell, respectively . Although several types of liposome-based nanocarriers have been approved by Food and Drug Administration (FDA) for clinical uses, liposomes are unstable in physiological media and thus further multifarious processes (with additional materials) are required to improve their stability. , Mesoporous silica NPs with tailorable interior/exterior surface properties can be designed to selectively carry hydrophilic and hydrophobic drugs of interest .…”

64CuCl2 PET Imaging of 4T1-Related Allograft of Triple-Negative Breast Cancer in Mice

“…With the help of machine-learning, non-FDG PET explorations may lead to better understanding of tumoral features and related prognosis factors [ 27 ]. In vivo theranostic strategies could also benefit from nanomedicines, able to carry both diagnostic (e.g., 64 Cu for PET, Gd(III) for MRI) and therapeutic compounds [ 28 ].…”

A Bionic Self-Assembly Hydrogel Constructed by Peptides With Favorable Biosecurity, Rapid Hemostasis and Antibacterial Property for Wound Healing

“…Hydrogels could contribute to promoting the hemostatic plug formation and form a physical barrier at the bleeding site ( Xiao et al, 2017 ). It also could be employed as carriers of multiple molecules, such as antimicrobial agents and growth factors ( He et al, 2019 ; Yan et al, 2021a ; Xue et al, 2022 ). For these reasons, hydrogels are identified as the most appropriate biomaterials for facilitating wound healing.…”